PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Raised against granulocytes of mouse origin

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 10⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C¹⁹. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8¹⁹. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4²⁰.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity², in vivo depletion^3-5,9, immunoprecipitation¹, immunohistochemical staining⁶ (including paraffin-embedded sections^9,16,33-35, acetone-fixed frozen sections¹¹ and zinc-fixed sections¹⁵), and Western blotting⁷. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)²⁰.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Additional Product Notes

BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)

Product Citations

1. Wang X, et al. 2019. Cell Res. 29:787. PubMed
2. Lang J, et al. 2020. Nat Commun. 11:1338. PubMed
3. Däbritz J, et al. 2016. Sci Rep. 6:20584. PubMed
4. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
5. Tripathi H, et al. 2020. J Mol Cell Cardiol. 149:95. PubMed
6. McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed
7. Kim JS, et al. 2020. Immunity. 54(1):176-190.e7. PubMed
8. Giambra V et al. 2018. Cell stem cell. 23(5):714-726 . PubMed
9. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
10. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
11. Lutzmann M, et al. 2019. Cell Rep. 28:2851. PubMed
12. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
13. Liang Q, et al. 2022. iScience. 25:104043. PubMed
14. Wang H, et al. 2019. Immunotherapy. 11:101. PubMed
15. Wang X, et al. 2020. Signal Transduct Target Ther. 5:35. PubMed
16. Kobayashi H, et al. 2020. STAR Protoc. 1:100078. PubMed
17. Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed
18. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
19. Lebratti T, et al. 2021. eLife. 10:00. PubMed
20. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
21. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
22. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
23. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
24. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
25. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
26. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
27. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
28. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
29. Li L, et al. 2015. J Am Soc Nephrol. 26: 2183-2197. PubMed
30. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
31. Vogel AB, et al. 2021. Nature. 592:283. PubMed
32. Bugler-Lamb AR, et al. 2021. Mol Metab. 49:101197. PubMed
33. Mishra A, et al. 2012. J Biol Chem. 287:44173. PubMed
34. Tripathi H, et al. 2020. Stem Cell Rev Rep. 0.953472222. PubMed
35. Jamali A, et al. 2020. Cell Reports. 32(9):108099. PubMed
36. Chatterjee D, et al. 2021. Cell Reports. 35(2):108996. PubMed
37. Haka A, et al. 2012. PLoS One. 7:e44823. PubMed
38. Kobayashi H, et al. 2020. Cell Reports. 28(1):145-158.e9.. PubMed
39. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
40. Garcia-Bonilla L, et al. 2014. J Immunol. 193:2531. PubMed
41. Arcipowski K, et al. 2016. PLoS One. 11: 0162515. PubMed
42. Giampazolias E, et al. 2021. Cell. . PubMed
43. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
44. Li L, et al. 2014. J Immunol. 192:1034. PubMed
45. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
46. Wang Z, et al. 2020. J Cell Mol Med. . PubMed
47. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
48. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
49. Deliyannis G, et al. 2021. JCI Insight. 6:. PubMed
50. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
51. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
52. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
53. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
54. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
55. Zhang X, et al. 2022. J Exp Clin Cancer Res. 41:246. PubMed
56. Matsushita N, et al. 2016. Sci Rep. 6:31266. PubMed
57. Petriello MC, et al. 2018. Toxicol Sci. 162:548. PubMed
58. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
59. Zheng QY, et al. 2019. Front Immunol. 10:1866. PubMed
60. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
61. Man N, et al. 2021. JCI Insight. 6:. PubMed
62. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed

RRID

AB_893561 (BioLegend Cat. No. 108427)
AB_893558 (BioLegend Cat. No. 108428)

Antigen Details

Structure

21-25 kD

Distribution

Granulocytes, monocytes

Cell Type

Granulocytes, Monocytes, Neutrophils

Biology Area

Immunology, Innate Immunity

Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID

17067 View all products for this Gene ID 546644 View all products for this Gene ID

UniProt

View information about Ly-6G Ly-6C on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

Certificate of Analysis